You can seek FDA approval to launch a generic drug before the expiration of DESCOVY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DESCOVY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DESCOVY:-

You can seek FDA approval to launch a generic drug before the expiration of EVOTAZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EVOTAZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EVOTAZ:-

You can seek FDA approval to launch a generic drug before the expiration of GENVOYA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GENVOYA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GENVOYA:-

You can seek FDA approval to launch a generic drug before the expiration of JADENU's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JADENU's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JADENU:-

You can seek FDA approval to launch a generic drug before the expiration of ODEFSEY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ODEFSEY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ODEFSEY:-

You can seek FDA approval to launch a generic drug before the expiration of ORENITRAM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ORENITRAM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ORENITRAM:-

You can seek FDA approval to launch a generic drug before the expiration of PREZCOBIX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PREZCOBIX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PREZCOBIX:-

You can seek FDA approval to launch a generic drug before the expiration of REYATAZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REYATAZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REYATAZ:-

You can seek FDA approval to launch a generic drug before the expiration of SAXENDA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SAXENDA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SAXENDA:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of TRUVADA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRUVADA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRUVADA:-